Find Clinical Trials & Studies

Visit the Research & Education Institute

Zanzalintinib Vs Everolimus in Participants With Locally Advanced or Metastatic NETs (STELLAR-31)

I'm Interested!

Please call
1-866-373-1464

A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors

Sex: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Neuroendocrine

Study Purpose

The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.

Principal Investigator
Amr Mohamed MD

Department/Division
Cancer (Digestive System)

UH IRB: STUDY20250638
StudyID: EXEL1225
ClinicalTrials.gov: NCT06943755

I'm Interested!

Please call
1-866-373-1464

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-866-373-1464